| Study Details | An open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in chronic inducible urticaria (CINDU) in adults in inadequately controlled by H1-antihistamines. |
| Protocol Number | CLOU064M12301 |
| Phase | III |
| Therapeutic Area | Dermatology |
| Subject Types | With Medical Condition |
| Indication | Chronic inducible urticaria |
| Principal Investigator | Dr Chris Tan Lixian |
| Investigator Product / Device | Remibrutinib (LOU064) |
| Sponsor | Novartis (Singapore) Pte Ltd |
